Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors

23. April 2026 aktualisiert von: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety, Anti-tumor Activity, Pharmacokinetic/Pharmacodynamic Characteristics of FXB0871 as Monotherapy in Participants With Selected Locally Advanced or Metastatic Solid Tumors

This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with selected locally advanced or metastatic solid tumors. In Part Ia, participants with selected solid tumors that have progressed after, are intolerant to, or are not suitable for standard therapy will receive FXB0871 in dose-escalation cohorts to determine the maximum tolerated dose and/or recommended phase 2 dose. In Part Ib, participants with PD-(L)1-resistant non-small cell lung cancer or hepatocellular carcinoma will receive FXB0871 in dose-expansion cohorts to further evaluate antitumor activity, safety, and dose optimization.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This first-in-human study consists of a dose-escalation part (Part Ia) and a dose-expansion part (Part Ib). In Part Ia, adults with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determinde dose cohorts using a Bayesian optimal interval design. The planned dosing schedule is every 2 weeks, with a dose-limiting toxicity observation period of the first 2 treatment cycles. Additional intermediate dose levels, cohort expansion, and schedule optimization to every 3 or 4 weeks may be allowed according to protocol-defined safety, PK/PD, and preliminary antitumor activity data.

Part Ib will start after determination of the monotherapy recommended phase 2 dose (RP2D). Cohort A will enroll participants with PD-(L)1-resistant locally advanced or metastatic non-small cell lung cancer and randomize them 1:1 to receive FXB0871 at the RP2D or at a lower dose selected on the basis of Part Ia data. Cohort B will enroll participants with PD-(L)1-resistant locally advanced or metastatic hepatocellular carcinoma to receive FXB0871 at the RP2D. Participants may continue study treatment for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

Studientyp

Interventionell

Einschreibung (Geschätzt)

138

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

  • China
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200000

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Signed informed consent.
  • Age ≥18 years.
  • Histologically confirmed selected locally advanced or metastatic solid tumor with progression on, intolerance to, or no suitable standard therapy.
  • ECOG performance status 0 or 1.
  • At least one measurable lesion per RECIST v1.1.
  • Pretreatment tumor tissue available (archival or fresh biopsy).
  • Life expectancy ≥12 weeks.
  • Oxygen saturation ≥92% on room air.
  • Left ventricular ejection fraction >50%.
  • Adequate hematologic, coagulation, renal, hepatic, and cardiac function.
  • Women of childbearing potential and sexually active men must use highly effective contraception.
  • Tumor-specific eligibility applies, including prior anti-PD-(L)1 treatment failure for the selected cohorts.

Key Exclusion Criteria:

  • Systemic anti-cancer therapy, major surgery, or radical radiotherapy within 4 weeks before first dose.
  • Prior treatment with IL-2, IL-15, or IL-7.
  • Active autoimmune disease requiring systemic treatment or immunodeficiency.
  • Systemic corticosteroids (≥10 mg/day prednisone equivalent) or other immunosuppressive therapy within 28 days before first dose, with limited protocol-defined exceptions.
  • Active or untreated central nervous system metastases, carcinomatous meningitis, or leptomeningeal disease.
  • Uncontrolled infection or clinically significant unresolved toxicities from prior therapy.
  • Clinically significant cardiovascular/cerebrovascular disease, uncontrolled effusions/ascites, uncontrolled hypertension, or QTcF >470 ms.
  • Active hepatitis B/C, syphilis, or HIV infection.
  • Clinically significant interstitial lung disease or active noninfectious pneumonitis.
  • Pregnancy or breastfeeding.
  • Any other serious medical or psychiatric condition that, in the investigator's judgment, would make participation inappropriate.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm1：Part Ia Dose Escalation
Participants with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determined dose-escalation cohorts or at intermediate dose levels every 2 weeks
Biologisch: Intervention1：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Part Ia every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Andere Namen:
  • TEV-56278
Experimental: Arm2：Part Ib Dose Expansion (NSCLC, RP2D)
Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologisch: Intervention2：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Andere Namen:
  • TEV-56278
Experimental: Arm3：Part Ib Dose Expansion(NSCLC, <RP2D)
Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at a selected lower dose than RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologisch: Intervention3：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Andere Namen:
  • TEV-56278
Experimental: Arm4：Part Ib Dose Expansion(HCC, RP2D)
Participants with locally advanced or metastatic IO-resistant HCC will receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologisch: Intervention4：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Andere Namen:
  • TEV-56278

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence and severity of dose-limiting toxicities (DLTs) in Phase Ia
Zeitfenster: First 2 cycles after first dose (each cycle = 14 days; approximately 28 days).
Percentage of participants with protocol-defined DLTs during the DLT observation period in the dose-escalation phase
First 2 cycles after first dose (each cycle = 14 days; approximately 28 days).
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia
Zeitfenster: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first
Safety assessed by the incidence of treatment-emergent adverse events, serious adverse events, AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia.
From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first
Objective response rate (ORR) in Phase Ib
Zeitfenster: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
ORR defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 in Phase Ib.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Objective response rate (ORR) in Phase Ia
Zeitfenster: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Objective response rate (ORR), defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed per RECIST v1.1 in Phase Ia.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR) in Phase Ia
Zeitfenster: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed per RECIST v1.1 in Phase Ia.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Duration of response (DOR) in Phase Ia
Zeitfenster: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.
From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS) in Phase Ia
Zeitfenster: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.
From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Peak serum concentration (Cmax)
Zeitfenster: Predose up to Day 8
Maximum observed concentration
Predose up to Day 8
Time to maximum observed concentration (Tmax)
Zeitfenster: Predose up to Day 8
Time to maximum observed drug concentration
Predose up to Day 8
Area under the serum concentration-time curve (AUC0-last)
Zeitfenster: Predose up to Day 8
Area under the serum concentration-time curve from time 0 to last measurable drug concentration
Predose up to Day 8
Area under the serum concentration-time curve (AUC0-∞)
Zeitfenster: Predose up to Day 8
Area under the concentration-time curve from time zero (pre-dose) extrapolation to infinite time
Predose up to Day 8
Area under the serum concentration-time curve (AUCtau)
Zeitfenster: Predose up to Day 8
Area under the concentration-time curve over the dosing interval
Predose up to Day 8
Trough concentration (Ctrough)
Zeitfenster: up to Day 8
Observed concentration at the end of a dosing interval, immediately before next administration
up to Day 8
Clearance (CL)
Zeitfenster: Predose up to Day 8
Systemic (total body) clearance following iv administration
Predose up to Day 8
Volume of distribution (Vz)
Zeitfenster: Predose up to Day 8
Volume of distribution following iv administration
Predose up to Day 8
Half-life (t1/2)
Zeitfenster: Predose up to Day 8
Terminal phase half-life
Predose up to Day 8
Average concentration (Cavg)
Zeitfenster: Predose up to Day 8
Average concentration over a dosing interval
Predose up to Day 8
Accumulation ratio (Rac)
Zeitfenster: Predose up to Day 8
Accumulation ratio
Predose up to Day 8
Incidence and severity of AEs/SAEs and AEs leading to dose modification or discontinuation in Phase Ib
Zeitfenster: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first.
Safety and tolerability in the dose-expansion phase.
From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first.
ORR by modified RECIST (mRECIST) in the HCC cohort of Phase Ib
Zeitfenster: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
ORR in participants with hepatocellular carcinoma assessed by mRECIST.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
Disease control rate (DCR) in Phase Ib
Zeitfenster: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or SD, as assessed per RECIST v1.1 in Phase Ib.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Time to response (TTR) in Phase Ib
Zeitfenster: From first dose to first documented CR or PR (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Time to response (TTR), defined as the time from first dose to the first documented CR or PR, as assessed per RECIST v1.1 in Phase Ib.
From first dose to first documented CR or PR (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Duration of response (DOR) in Phase Ib
Zeitfenster: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.
From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Title:Progression-free survival (PFS) in Phase Ib
Zeitfenster: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.
From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Overall survival (OS) in Phase Ib
Zeitfenster: From first dose until death from any cause (approximately up to 24 months).
Overall survival measured from first dose to death from any cause.
From first dose until death from any cause (approximately up to 24 months).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Mai 2026

Primärer Abschluss (Geschätzt)

23. April 2030

Studienabschluss (Geschätzt)

18. November 2030

Studienanmeldedaten

Zuerst eingereicht

7. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. April 2026

Zuerst gepostet (Tatsächlich)

30. April 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. April 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. April 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • FXB0871-I101

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Hepatozelluläres Karzinom

Klinische Studien zur Intervention1：FXB0871

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Cameroon

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren